Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
04:33am, Monday, 25'th Aug 2025
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk"
Novo Nordisk: Undervalued Pharma Heavyweight With Upside Potential
10:30am, Sunday, 24'th Aug 2025
Novo Nordisk is deeply undervalued, trading at a forward P/E of 14, despite 20%+ top and bottom-line growth and dominant weight-loss market share. The anti-obesity market is set to grow nearly 10x by
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
08:00am, Sunday, 24'th Aug 2025
Some analysts say Eli Lilly's daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial
Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other Overvalued
08:55pm, Saturday, 23'rd Aug 2025
Novo Nordisk and Eli Lilly both declined significantly in the last months. This was mainly caused by efficacy uncertainty, further competition and political headwinds. Despite the sell-offs, I current
NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
06:57pm, Friday, 22'nd Aug 2025
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
04:44pm, Friday, 22'nd Aug 2025
NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma's Path to Dominance
12:13pm, Friday, 22'nd Aug 2025
Key Points in This Article: Novo Nordisk (NVO) pioneered GLP-1 drugs with Ozempic and Wegovy, but lost ground to Eli Lilly's Mounjaro and Zepbound.
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Friday, 22'nd Aug 2025
LOS ANGELES , Aug. 22, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/S
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
09:35am, Friday, 22'nd Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
08:45am, Friday, 22'nd Aug 2025
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The
Novo Nordisk: This Options Strategy Was Profitable Even With The Stock Down
08:15am, Friday, 22'nd Aug 2025
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international markets and new launches support the outlook. My updated fair value estima
The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO
03:31pm, Thursday, 21'st Aug 2025
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
BENSALEM, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
